Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic Gets Extra FDA Attention To Hasten Approval Of Next-Gen Insulin Pump

This article was originally published in The Gray Sheet

Executive Summary

CDRH has formed a close working partnership with Medtronic to facilitate quick approval for a next-generation insulation pump-glucose monitor, offering an illustration of what the center’s future plans might be for addressing devices with breakthrough potential.


Related Content

US FDA Approves First 'Artificial Pancreas' In Medtronic's MiniMed 670G
Medtronic Launches U.S. Trial For Predictive Glucose Monitor-Pump System
Leap Ahead With EAP? FDA Proposes New Expedited PMA Pathway
Medtronic Sees Long-Awaited Approval Of MiniMed 530G As A Big Step In Artificial Pancreas “Journey”
Artificial Pancreas Guidance Allows For More Flexibility In Trial Design


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts